Treatment

Therapeutic ultrasound for brain disorders

MEDICAL APPLICATIONS OF THE SONOPROBE

Given the neurosurgical specialty of Professor Carpentier, the SonoProbe was designed for the treatment of brain disorders including brain tumors, epilepsy, metastases, meningiomas, … whose annual incidence in Europe and the USA exceeds 400,000 patients. These are indications that will be developed in future clinical studies.

In addition, the SonoProbe is adaptable for the treatment of diseases in organs such as the lung or in organs located behind bone structures such as the liver.

 

MEDICAL APPLICATIONS OF THE SONOCLOUD®

The primary objective of the SonoCloud® implant is to increase the intracerebral bioavailability of chemotherapy. It is therefore perfectly suited to the treatment of primary brain tumors (gliomas, glioblastomas, astrocytomas, …) as well as secondary brain tumors (metastases) … thus, the annual incidence in Europe and the USA exceeds 250,000 patients. The clinical study currently underway is for patients with glioblastoma.

More generally, the SonoCloud® implant allows for the passage of many substances that are currently not able to enter the brain because of the blood-brain barrier. It can therefore be a potential tool for the treatment of neurodegenerative diseases such as Alzheimer’s Disease.

  • unnamed-2
    unnamed-3

     
  • News CarThera

    13.12.2018
    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.

    09.06.2018
    ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

    Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

    Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

    18.05.2018
    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at contact@carthera.eu and come to Booth 527 at the France Pavilion.